GSK (BUE:GSK) FFO


BUE:GSK GSK PLC BUE:GSK
65 GF Score
Price ARS20,190.00
GF Value ARS16,809.73
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK FFO?

FFO (Funds from operations) only applies to REITs.

BUE:GSK
65GF Score
GSK PLC BUE:GSK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is GSK (BUE:GSK) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of ARS20,190.00 is trading 20.1% above its estimated GF Value™ of ARS16,809.73. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for BUE:GSK:

  • FFO:
  • GF Value™: ARS16,809.73 vs. price of ARS20,190.00 (20.1% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the BUE:GSK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
65GF Score

Get the complete analysis for BUE:GSK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS20,190.00
Price
ARS16,809.73
GF Value